VWA
ECYT

V Wealth Advisors’s Endocyte, Inc. Common Stock ECYT Stock Holding History

V Wealth Advisors’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed – – 803
2017
Q2 		$0 Buy
+100
New +$215 ﹤0.01% 846

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

V Wealth Advisors's ECYT Position: Q3 2017 in Review

V Wealth Advisors sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2017, closing a stake of 100 shares.

V Wealth Advisors first reported a position in ECYT in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 63 funds tracked by Wall St. Rank hold ECYT as of Q3 2017.

  • V Wealth Advisors reported no remaining Endocyte, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • V Wealth Advisors sold 100 Endocyte, Inc. Common Stock shares in Q3 2017.
  • V Wealth Advisors first reported a position in Endocyte, Inc. Common Stock in Q2 2017 and held it in 1 quarter.
  • V Wealth Advisors's Endocyte, Inc. Common Stock position peaked at $0 in Q2 2017.
  • 63 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.